Physician profile
Cindy E Atkins
NPI 1740441591
$4,561.26
in general payments reported to CMS, 2019-2025
33 companies · $889 in 2025
The $889 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $566 · 2020: $343 · 2021: $722 · 2022: $328 · 2023: $555 · 2024: $1,158 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,602.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $757.94 | 2021-2025 | Vraylar |
| Pfizer INC. | $543.81 | 2019-2025 | |
| Lilly USA, LLC | $479.12 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $380.39 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $349.37 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $290.42 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $194.60 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Phathom Pharmaceuticals, INC. | $186.76 | 2024-2025 | Voquezna |
| Abbott Laboratories | $163.63 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $131.63 | 2020-2023 | |
| Amgen INC. | $123.41 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $99.24 | 2024-2025 | Caplyta |
| Astellas Pharma US INC | $96.33 | 2019-2025 | Veozah |
| Dynavax Technologies Corporation | $85.55 | 2024 | Heplisav-B |
| Astrazeneca Pharmaceuticals LP | $77.40 | 2019-2024 | Farxiga |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $65.16 | 2020-2025 | |
| Gilead Sciences, INC. | $58.97 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.19 | 2024 | |
| Xeris Pharmaceuticals, INC. | $46.12 | 2023 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $45.74 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.48 | 2020-2021 | |
| Allergan, INC. | $42.00 | 2020 | |
| Daiichi Sankyo INC. | $36.05 | 2019-2022 | |
| Axsome Therapeutics, INC. | $28.95 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.83 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.81 | 2022 | |
| Janssen Pharmaceuticals, INC | $24.05 | 2019 | |
| Amarin Pharma, INC. | $20.98 | 2019 | |
| Inspire Medical Systems, INC. | $20.55 | 2025 | Inspire |
| Exact Sciences Corporation | $19.52 | 2024 | Cologuard Collection Kit |
| Circassia INC. | $16.78 | 2019 | |
| Almatica Pharma LLC | $14.94 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Atkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.